Trial · NCT06906341
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341, Phase 2, Recruiting, Corcept Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers. Trials, record NCT06906341. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06906341
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- NCT number
- NCT06906341
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 270 participants, estimated
- Lead sponsor
- Corcept Therapeutics
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
- Interventions
- Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
- First posted
- 2025-04-02
- Last updated
- 2026-07-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) | Date of first dose until PD or death, up to 18 months | To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
| Secondary | Objective Response Rate (ORR) | Date of first dose until PD or death, up to 18 months | To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
| Secondary | Best Overall Response Rate (BOR) | Date of first dose until PD or death, up to 18 months | To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
| Secondary | Duration of Response (DOR) | Time of first objective response until PD or death, up to 18 months | To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
| Secondary | Clinical Benefit Rate (CBR) | Week 24 | To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
| Secondary | Overall Survival (OS) | Date of first dose up to 6, 12, and 18 months | To evaluate the probability of OS survival at 6, 12, and 18 months. |
| Secondary | Number of patients with one or more adverse events | Date of first dose up to 30 days after last dose | |
| Secondary | Area under the plasma concentration-time curve (AUC) of relacorilant | On Cycle 1 Day 8 (each cycle is 28 days) | To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
| Secondary | Maximum plasma concentration (Cmax) of relacorilant | On Cycle1 Day 8 (each cycle is 28 days) | To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
| Secondary | Trough plasma concentrations (Cmin) of relacorilant | On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days) | To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06906341
GET https://conductscience.org/api/trials/v1/NCT06906341/registered